Immuron Earlier Filed For Mixed Shelf Offering Of Up To $15M
$IMRN
Biotechnology: Pharmaceutical Preparations
Health Care
-6-K
-6-K
Save time and jump to the most important pieces.
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
Sales Highlights: Global•FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp)•June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarter Australia •FY 2024 AUD$3.7 million up 223% on pcp•June 2024 Quarter AUD$1.0 million up 200% on pcp and 11% on prior quarter USA •FY 2024 Record sales of AUD$1.1 million up 74% on pcp•June 2024 Quarter AUD$0.3 million up 546% on pcp; down 1% on prior quarter Canada•FY2024 AUD$0.1 million up 6637% on pcp MELBOURNE, Australia, July 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce record sales (unaudited) of T
-6-K
To address this need, Immuron is developing IMM-529 as an adjunctive therapy in combination with standard of care antibiotics for the prevention and/or treatment of recurrent CDI. IMM-529 antibodies targeting C. diff may help to clear CDI infection and promote a quicker re-establishment of normal gut flora, providing an attractive oral preventative for recurrent CDI.
MELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the 21st Virtual Investor Summit Microcap Event (November 21, US Eastern Time). A copy of the presentation is available on the Company's website. https://www.immuron.com.au/corporate-presentations/ This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT: Steven LydeamoreChief Executive [email protected] About ImmuronImmuron Limited ((ASX: IMC, NASDAQ:IMRN), is an Australian biopharmaceutic
MELBOURNE, AUSTRALIA / ACCESSWIRE / November 18, 2024 / Immuron Limited (NASDAQ:IMRN) has one commercial product and two pipeline assets in three clinical programs for the treatment of gut mediated diseases. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.Event: Q4 Investor SummitPresentation Time: 10:30am - 11:00am ETLocation: https://www.webcaster4.com/Webcast/Page/3075/51674The theme is 40 micro-cap companies with a catalyst and/or strong performance in the current market.Take a deep dive with the best Investors in MicroCapLive Q & AComplimentary to Qualified Investors. Please REGISTER HERE.About the Investor SummitThe Investor Summit
MIAMI, Oct. 30, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsor:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) [email protected]
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today. Roger was appointed as a Director in 2012 and served as Non-Executive Chairman from 2012 to 2023. Immuron over the past few years has been ongoing with significant positive change. We have accelerated our commercial activities through higher level of marketing, improved channel management and strategic intent. Our scientific endeavours are bearing results with strong clinical data supporting IMC's unique hyper-immune colos
MELBOURNE, Australia, May 05, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of Steven Lydeamore as Chief Executive Officer (CEO) of the Company effective 27 June 2022. Mr. Lydeamore has 30 years international pharmaceutical experience, working in Australia, Canada and USA. Mr. Lydeamore brings valuable international experience having spent eleven years working at Canadian global pharmaceutical company Apotex Inc., and four years for Mayne Pharma (USA) Limited. This i
MELBOURNE, Australia, March 16, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of Paul Brennan as an independent Non-Executive Director of the Company with effect from today. Mr Brennan has extensive experience in the health system through his clinical background and commercial exposure with various multinational companies. Mr Brennan was Chief Executive Officer (CEO) of PolyNovo Limited (ASX:PNV) for 7 years from 2015 to 2021 and took the company from $30M to a high